Ratna1, I think the most important difference between Amarin selling V, and a well establish BP, is that the BP wouldn’t have the same burden of paying a sales force to sell V, they have a much bigger established sales force in place, and they have well established relationships with all the key players like doctors, PBM’s, and pharmacies etc. A BP may be able to cut the cost of goods enough to lower the price enough to where the generics can’t compete. That’s why I believe a BO is in the works or definitely on the table for serious consideration by big Pharma. It just has to be. My main concern against any near term buyout is the restricted current capacity issue for massive accelerated growth worldwide.